Study Overview: ACTOv Trial
Title: Adaptive ChemoTherapy for Ovarian Cancer (ACTOv)
This is a phase II study to test a new way of treating ovarian cancer using a drug called carboplatin. It focuses on women whose cancer has returned after treatment and is still sensitive to platinum-based therapies.
What is Adaptive Therapy?
Adaptive therapy (AT) is a fresh approach that adjusts drug doses based on how well patients respond to treatment. The goal is to balance the fight between sensitive and resistant cancer cells, potentially improving outcomes.
Study Details
- Participants: 80 women with relapsed high-grade ovarian cancer.
- Groups: Randomly assigned to either standard treatment or adaptive therapy.
- Treatment Schedule: Carboplatin administered intravenously every 21 days, up to 6 cycles for standard treatment and 12 cycles for adaptive therapy.
- Key Measurement: Progression-free survival and other health outcomes.
Ethics and Sharing Results
The study has ethical approval and results will be shared in scientific journals to inform the medical community.
How We Support Clinical Trials
Clinical trials are essential for developing effective treatments. Our AI-driven platform, DocSym, helps clinicians by providing:
- Consolidated Knowledge: Access to ICD-11 standards, clinical protocols, and research.
- Operational Efficiency: Mobile apps for scheduling, treatment monitoring, and telemedicine.
- Enhanced Workflows: AI tools that reduce paperwork and improve patient care.
Learn more about how our solutions can support your clinic at aidevmd.com.
